BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38219707)

  • 21. Molecular subtyping and prognostic risk characterization of head and neck squamous cell carcinoma based on lysosome-related genes.
    Zhang A; Jin Y; Zou X; Zhang S
    Medicine (Baltimore); 2023 Jul; 102(28):e34275. PubMed ID: 37443469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer.
    Huang L; David O; Cabay RJ; Valyi-Nagy K; Macias V; Zhong R; Wenig B; Feldman L; Weichselbaum R; Spiotto MT
    Clin Cancer Res; 2019 Mar; 25(6):1795-1808. PubMed ID: 30573692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy.
    Patil S; Tawk B; Grosser M; Lohaus F; Gudziol V; Kemper M; Nowak A; Haim D; Tinhofer I; Budach V; Guberina M; Stuschke M; Balermpas P; Rödel C; Schäfer H; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Boeke S; Zips D; Baretton GB; Baumann M; Krause M; Löck S; Linge A;
    Radiother Oncol; 2022 Feb; 167():300-307. PubMed ID: 34999136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 25. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
    Leblanc O; Vacher S; Lecerf C; Jeannot E; Klijanienko J; Berger F; Hoffmann C; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Bieche I; Le Tourneau C; Kamal M
    Cancer Biol Med; 2020 Feb; 17(1):208-217. PubMed ID: 32296588
    [No Abstract]   [Full Text] [Related]  

  • 27. A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes.
    Foy JP; Bazire L; Ortiz-Cuaran S; Deneuve S; Kielbassa J; Thomas E; Viari A; Puisieux A; Goudot P; Bertolus C; Foray N; Kirova Y; Verrelle P; Saintigny P
    BMC Med; 2017 Sep; 15(1):165. PubMed ID: 28859688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of immune-related lncRNA panel for predicting immune checkpoint blockade and prognosis in head and neck squamous cell carcinoma.
    Li Q; Shen Z; Shen Y; Deng H; Shen Y; Wang J; Zhan G; Zhou C
    J Clin Lab Anal; 2022 Jun; 36(6):e24484. PubMed ID: 35561269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Subtypes Based on Cell Differentiation Trajectories in Head and Neck Squamous Cell Carcinoma: Differential Prognosis and Immunotherapeutic Responses.
    Huang ZD; Liu ZZ; Liu YY; Fu YC; Lin LL; Hu C; Gu HY; Wei RX
    Front Immunol; 2021; 12():791621. PubMed ID: 35003112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Six Glycolysis-Related Genes as Prognostic Risk Markers Can Predict the Prognosis of Patients with Head and Neck Squamous Cell Carcinoma.
    Chen L; He X; Yi S; Liu G; Liu Y; Ling Y
    Biomed Res Int; 2021; 2021():8824195. PubMed ID: 33628816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Correlation of an Autophagy-Related Gene Signature in Patients with Head and Neck Squamous Cell Carcinoma.
    Yang C; Mei H; Peng L; Jiang F; Xie B; Li J
    Comput Math Methods Med; 2020; 2020():7397132. PubMed ID: 33456497
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Cao CH; Liu R; Lin XR; Luo JQ; Cao LJ; Zhang QJ; Lin SR; Geng L; Sun ZY; Ye SK; Yu ZY; Shi Y; Xia X
    Int J Biol Sci; 2021; 17(7):1744-1756. PubMed ID: 33994859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FAM3 Family as Prognostic Factors for Head and Neck Squamous Cell Carcinoma.
    Liao C; Wang Q; An J; Wang H; Xiao L; Long Q; Zhao H; Liu J; Guan X
    Comb Chem High Throughput Screen; 2023; 26(3):539-558. PubMed ID: 35538834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Dunn LA; Fury MG; Xiao H; Baxi SS; Sherman EJ; Korte S; Pfister C; Haque S; Katabi N; Ho AL; Pfister DG
    Ann Oncol; 2017 Oct; 28(10):2533-2538. PubMed ID: 28961834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and validation of a fourteen- innate immunity-related gene pairs signature for predicting prognosis head and neck squamous cell carcinoma.
    Zhang F; Liu Y; Yang Y; Yang K
    BMC Cancer; 2020 Oct; 20(1):1015. PubMed ID: 33081731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
    Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD
    Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of
    Zhang P; Zhao Y; Xia X; Mei S; Huang Y; Zhu Y; Yu S; Chen X
    Oncoimmunology; 2023; 12(1):2203073. PubMed ID: 37089448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols.
    Haring CT; Kana LA; Dermody SM; Brummel C; McHugh JB; Casper KA; Chinn SB; Malloy KM; Mierzwa M; Prince MEP; Rosko AJ; Shah J; Stucken CL; Shuman AG; Brenner JC; Spector ME; Worden FP; Swiecicki PL
    Cancer; 2023 Sep; 129(18):2817-2827. PubMed ID: 37162461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prognostic mRNA expression signature of four 16q24.3 genes in radio(chemo)therapy-treated head and neck squamous cell carcinoma (HNSCC).
    Wintergerst L; Selmansberger M; Maihoefer C; Schüttrumpf L; Walch A; Wilke C; Pitea A; Woischke C; Baumeister P; Kirchner T; Belka C; Ganswindt U; Zitzelsberger H; Unger K; Hess J
    Mol Oncol; 2018 Dec; 12(12):2085-2101. PubMed ID: 30259648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification and Analysis of Senescence-Related Genes in Head and Neck Squamous Cell Carcinoma by a Comprehensive Bioinformatics Approach.
    Deng L; Mi J; Ruan X; Zhang G; Pan Y; Wang R
    Mediators Inflamm; 2022; 2022():4007469. PubMed ID: 36299414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.